Pharma CEOs: What Should They Say?
Executive Summary
On the eve of the Big Hearing, communication and business strategists offer advice on how to get the grilling to go as well as possible.
You may also be interested in...
HHS Rebate Plan A Leap Of Faith? Lower Costs Hinge On Drug Firm, Plan Response
HHS seeks input on how stakeholders might adjust to a system without rebates and requests comments on three actuarial reports that attempt to project the financial impact of the change.
US FDA Pursuing Two-Track Approach To Regulatory Convergence For Cell and Gene Therapies
Discussions through the WHO are aimed at educating low- and middle-income countries, while efforts with ‘the larger regulators’ aim to reduce the development burden for products targeting ultra-rare diseases, CBER director Peter Marks tell DIA.
Peter Marks On How He Wants To Prepare For The Next Pandemic
Acknowledging the toll that vaccine opponents have taken on FDA operations, the CBER director emphasizes the need to create stand-by manufacturing capacity, conduct faster studies in special populations, and better understand the mRNA platform.